EGFR and non-small cell lung carcinoma: As the third generation EGFR-TKI new drug, Osimertinib has the same clinical effect as Gefitinib in the treatment of non-small cell lung cancer complicated with EGFR gene mutation, but PFS is significantly longer than Gefitinib group, and the adverse reaction rate is lower, which is worthy of clinical application.